Background: This systematic review addresses the controversy over the decision to anticoagulate patients with
T his systematic review addresses the ongoing clinical controversy over the decision to withhold or administer systemic anticoagulation to patients with subsegmental pulmonary embolism (SSPE). In a recent topical review of SSPE, Long and Koyfman 1 concluded "Controversy has occurred concerning the potential dangers of these lesions and whether treatment is warranted." A social media poll conducted in April 2016 among "followers" of a thrombosisoriented microblog (https://twitter.com/klinelab/sta tus/724298338334552066) asked the question "Which is in more need of a definitive randomized controlled trial?: 1. Exclusion of PE in pregnancy; 2. + or -treatment of subsegmental PE; 3. Half dose lytics; or 4. D-dimer in children." Fifty-seven percent of 243 respondents voted for option 2. These opinions reflect the lack of data from randomized controlled trials to answer the question. 2 The high interobserver variability between blinded, expert radiologists at the detection of SSPE adds to the uncertainty. 3 In 2010, Carrier et al. 4 performed a systematic review of literature and found a 4.7% (95% confidence interval [CI] = 2.5%-7.6%) prevalence of SSPE. Surveys suggest clinical equipoise regarding the decision to treat or not treat SSPE in the absence of deep vein thrombosis (DVT) or cancer, and a recent clinical guideline suggests that it is reasonable to withhold anticoagulation. 5, 6 To our knowledge, no systematic literature review has directly addressed whether existing literature could provide estimates of outcomes of patients with SSPE who were treated or not treated with anticoagulation. Thus, the purpose of this concise systematic review with metaanalyses is to report the frequency of death, bleeding, and recurrent venous thromboembolism (VTE) in patients with SSPE based on the decision to treat or not treat with systemic anticoagulation.
METHODS
This study was registered at http://www.crd.york.ac. uk/PROSPERO/ on February 1, 2017 (CRD4201704 9372). Methods for paper selection and reporting follow the guidelines set forth by the PRISMA statement and those recommended by the MOOSE standardized reporting guidelines. 7, 8 Population This study included a population of patients with acute pulmonary embolism proven by computerized tomographic pulmonary angiography (CTPA) regardless of detector-row head number. Subsegmental PE was defined as a filling defect in a single pulmonary artery < 2.5 mm in diameter or a filling defect graded as <5% of total pulmonary vascular cross-sectional area using a standardized scoring system. 79 Patients were allowed from any setting. Full inclusion and exclusion criteria are described in further detail below.
Outcomes
The main question of this work was to determine the frequency of bleeding, VTE recurrence, and death for patients with SSPE, stratified by the decision to treat or not treat with systemic anticoagulation. Where possible, we sought to determine the presence or absence of cancer and concomitant DVT.
Literature Search Data Sources and Eligibility Criteria. A comprehensive search of the literature was performed by a medical librarian (TWE) in Ovid MEDLINE, PubMed, Embase, the Cochrane Library, Scopus, Web of Science, ClinicalTrials.gov, and Google Scholar. Bibliographies of relevant studies were also checked for additional references. All searches were performed in March 2017, and all databases were searched from inception. The complete search strategies for each database are reported in Data Supplement S1 (available as supporting information in the online version of this paper, which is available at http://onlinelibrary.wiley.com/d oi/10.1111/acem.13399/full). Database-specific subject headings and keyword variants for each of the three major concepts-pulmonary embolism, subsegmental location, and computed tomography-were identified and combined. Results were limited to the English language, and animal studies were excluded.
Selection Process
Two authors (AB and LKS) reviewed the results of the search for relevance and independently read the titles and abstracts of all retrieved citations if either reviewer believed the abstract was relevant. The same two authors then independently read the retained fulllength articles that passed the initial screen for inclusion in the final analysis and graded them on three levels of relevance: yes, no, or maybe. Discordances were resolved by consensus from a third author (JAK). We assessed interobserver reliability with raw percentage agreement and Cohen's kappa (j) weighted by [1 -abs(i -j)/(1 -k))] between the first two reviewers, where k = 3 (categories: yes, maybe, no), i is the category for one observer (from 1 to k with k equal to 1 for yes, 0.5 for unclear, 0 for no), and j is the category for the other observer (from 1 to k).
Inclusion and Exclusion Criteria
The initial inclusion criteria were as follows: studies of symptomatic patients who underwent objective diagnostic testing for suspected PE and had CTPA as the imaging criterion standard. Diagnosis of PE required pulmonary vascular imaging demonstrating a filling defect on CTPA. Papers had to include sufficient information to document the presence of SSPE, and the results had to include information on the presence or absence of anticoagulation treatment and the outcomes of interest (bleeding, VTE recurrence, or death assessed at least 30 days beyond diagnosis). Populations could be drawn from diagnostic or treatment studies, without restriction on where the patient was located at the time of diagnosis. Exclusions included studies of incidentally discovered SSPE in patients undergoing imaging to diagnose or monitor other diseases such as cancer. When necessary, we e-mailed the corresponding authors for additional data up to three times.
Quality Assessment
We graded study quality using the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2) and the Newcastle-Ottawa score, using a standard form. 10 Each study was graded as "low risk," "high risk," or "unclear risk" for bias in terms of selection of patients and reference standard. For patient selection, we considered a study low risk if it enrolled unselected patients with PE discovered under conditions similar to what a physician practicing in a hospital or emergency department setting might encounter. We considered patient selection bias to be high risk if paper or personal communication with the author indicated that patients were preselected by criteria that would bias the probability of SSPE discovery based on features of presentation (e.g., patients restricted to a certain age or predisposing diseases, preselection by a physician, nonambulatory populations, or predefined anatomic or severity criteria of PE on CTPA results). Papers were also deemed high risk if it could not be determined that patients presented on their own based on symptom perception (e.g., if the population included patients with CTs done for other disease surveillance rather than evaluation of PE). If the paper lacked detail to assess as either low or high risk, we deemed it unclear risk. We considered the reference standard at low risk of bias if all patients included had positive CTPA interpreted by a board-certified radiologist and if outcomes were followed equally for all patients for 3 months. Studies lacking sufficient criteria to understand patient selection or reference standard were deemed unclear risk.
Data Analysis
As the focus of this work is to compare outcomes of SSPE patients with and without anticoagulation, we generated two tables based on this designation that included the total number of PE+ patients as well as the number of SSPE+ patients who had each outcome. We assessed for heterogeneity between studies using the inconsistency indexes (I 2 and I 2 v ) for outcomes of VTE recurrence and death, where I 2 represents the percentage of the total variability in a set of effect sizes due to true heterogeneity, owing to between-studies variability; I 2 v includes a random effects correction term to account for variability in different populations sampled. 11 The absence of matched data precluded any odds or risk ratio analyses. The primary comparator between strata (anticoagulated or not) was the pooled proportion (computed from the random-effects model) of patients with SSPE who had bleeding, VTE recurrence, or death within 3 months (StatsDirect, v4.0).
RESULTS

Article Selection
A total of 1,512 references were identified through database searching (Figure 1 ). After removing 451 duplicates, 1,061 unique titles and abstracts were screened by two reviewers. We requested 105 papers for full-text review, from which 14 were retained. The raw agreement between the two reviewers was 89% with fair interobserver reliability (weighted j = 0.52; 95% CI = 0.31-0.73). Of the 14 that were selected for inclusion in this review, seven reported outcomes with anticoagulation and seven reported outcomes in patients with and without anticoagulation. Table 1 shows the characteristics of each study retained for full-length review.
Main Findings
For the included 14 studies in Table 1 , the pooled prevalence (random effects) of SSPE in all studies was 4.6% (95% CI = 1.8%-8.5%). I 2 was 99% suggesting noncombinability, whereas the funnel plot was asymmetric (Egger's p = 0.002), suggesting significant publication bias. We had desired to report rates of concomitant cancer or DVT, but no studies provided these data. Tables 2 and 3 show the outcomes of patients with SSPE based on decision to treat or not treat with anticoagulation. Heterogeneity for each outcome is presented below each table (Tables 2 and 3) ; I 2 ranged from a high of 78.6% (95% CI = 54.6%-87.2%) for VTE recurrence in patients treated with anticoagulation (Table 2 ) to a low of 42.5% (95% CI = 0%-77.6%) for death in patients not treated. These values of I 2 suggest moderate to high inconsistency and emphasize the need for a random-effects approach at pooling data. 22 The pooled frequency of bleeding among patients treated with anticoagulation was 8.1% (95% CI = 2.8%-15.8%). Of note, studies generally lacked definitions of bleeding. Data Supplement S2 (available as supporting information in the online version of this paper, which is available at http://onlinelibrary.wiley.com/doi/10.1111/acem. 13399/full) lists the available bleeding definitions for each study, if specified. No study reported the frequency of bleeding without anticoagulation. The pooled frequency of death within 90 days was 2.1% (95% CI = 0.3%-5.2%) for treated versus 3.0% (95% CI = 2.8%-8.6%) for untreated. The pooled frequency of VTE recurrence within 90 days was 5.3% (95% CI = 1.6%-10.9%) for treated versus 3.9% (95% CI = 4.8%-13.4%) for untreated. No paper provided adequate information to determine the rates of cancer or concomitant DVT. We had also intended to group studies by country of origin, but the low number of studies precluded this as a meaningful exercise.
Sensitivity Analyses
We first analyzed the death and VTE recurrence rates for five studies that had data for both treated and untreated patients. We then excluded one outlier study for each outcome (death, VTE recurrence, and bleeding) based on highest rank in standardized effect in terms of percentage contribution to the random-effects model. For both death rate and VTE recurrence in treated patients, den Exter et al. 15 accounted for the highest effect. With the study by den Exter excluded, the pooled 90-day mortality and VTE recurrence rates for treated SSPE were 1.1% (95% CI = 0.3%-2.5%; I 2 = 22.9% [95% CI = 0%-64.1%]) and 3.8% (95% CI = 2.0%-6.1%; I 2 = 76.3% [95% CI = 43.8%-86.6%]), respectively. For bleeding rate in treated patients, exclusion of Auer et al. 12 led to a bleeding rate of 5.0% (95% CI = 3.0%-7.4%, I 2 = 72.1% [95% CI = 8.4%-86%]). Similarly, subgrouping by low study bias did not substantially change any proportions.
DISCUSSION
This comprehensive systematic review of the literature performed in the spring of 2017 found 14 studies that reported outcomes for a small number of patients with SSPE treated with (n = 589) and without (n = 126) anticoagulation. The lack of precision in pooled data and high heterogeneity of the outcomes suggest that no inferences can be made about benefit or harm with either approach. The pooled death rates within 90 days, calculated using the random-effects model, for treated versus untreated were 2.1% (95% CI = 0.3%-5.2%) versus 3.0% (95% CI = 2.8%-8.6%), suggesting no clinically important difference, given the wide CIs. The pooled VTE recurrence rates of 5.3% (95% CI = 1.6%-10.9%) for treated versus 3.9% (95% CI = 4.8%-13.4%) for untreated patients similarly show no clear signal of benefit or harm. The pooled 90-day rate of bleeding was not reported in patients without treatment but was surprisingly high in anticoagulated patients, 8.1% (95% CI = 2.8%-15.8%), and was not significantly decreased in the sensitivity analysis (the bleeding rate with Auer et al. 12 excluded was 5.0% [95% CI = 3.0%-7.4%]). This 5% to 8% 90-day bleeding rate is considerably higher than the 0.9% (95% CI = 0.66% -1.16%) 90-day bleeding rate that has been reported in pooled data from clinical trials of treatment with vitamin K antagonists for VTE. 23 Moreover, it is not possible to determine from existing literature why physicians decided not to treat some patients with SSPE. Reasons could range from the fact that patients with SSPE were much healthier and without ongoing risks of VTE or they had end-stage medical conditions or high bleeding risk. Finally, the data show considerable heterogeneity with I 2 values ranging between 42.5 and 78.6% for the subsets in Tables 2  and 3 , suggesting inconsistencies in underlying risk factors and health status of enrolled patients. 
LIMITATIONS
Limitations include the fact that all of the pooled outcomes were aggregates of studies that had moderate to high heterogeneity (i.e., an I 2 > 50%), suggesting that the populations of the component studies had variable health states. The patient sample represented by the treatment studies may not represent the actual SSPE patient for which most clinicians would even consider withholding anticoagulation. Further, the high bleeding rate and relatively high VTE recurrence rate among treated patients imply that these patients had higher risk than most VTE populations, which, in turn, implies the presence of spectrum bias.
Despite these limitations, our data add to previous literature as the first systematic review that pooled data to assess the clinical effect of anticoagulation for SSPE. Our review was designed to find papers that reported outcomes of patients with SSPE, who, according to usual care protocols, were either anticoagulated or not anticoagulated. Prior systematic reviews had different objectives. In 2010, Carrier et al. 4 was focused on the prevalence of SSPE and the relationship to CT scanning detector head row status. In a 2016 systematic review, Yoo et al. 2 sought randomized controlled clinical trials of SSPE, and the authors found none. Likewise, we found no controlled clinical trials. Nonetheless, we believe that the available outcome data from studies that treated and did not treat SSPE provide three important inferences. First, their deficiencies show the need for a randomized trial. Second, the lack of difference in death or VTE recurrence justifies the need for a randomized trial from an ethical standpoint. If the data demonstrated a large difference in VTE recurrence or death without anticoagulation, this would have precluded the inference of equipoise. Finally, the data suggest that the current state of the art for deciding to treat or not treat a patient with SSPE (and no DVT) is best left to clinical judgment and possibly a shared decision-making model with the patient.
CONCLUSIONS
Currently published literature allows no clear inference regarding risk or benefit of anticoagulation for patients with isolated subsegmental pulmonary embolism. Studies that reported outcomes for subsegmental pulmonary embolism patients treated or not treated with anticoagulation showed moderate to high inconsistency between studies, and we found no controlled clinical trials. Comparison of the pooled data suggests clinical equipoise. These data highlight the need for a controlled trial.
